Molecular Partners Ag (MOLN) Enterprise Value (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Enterprise Value of -$100587.1 for Q1 2026, up 100.0% year-on-year from -$50293.6 in Q1 2025, and down 666.56% on a QoQ basis from -$13121.8 in Q4 2025.
Molecular Partners Ag (MOLN) Enterprise Value (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Enterprise Value for 7 consecutive years, with -$100587.1 the latest figure, recorded in Q1 2026.
- Quarterly Enterprise Value rose 100.0% year-over-year to -$100587.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100587.1 (up 100.0% YoY) and the FY2025 annual result came in at -$13121.8, up 99.99% from the prior year.
- Enterprise Value retreated to -$100587.1 in Q1 2026 per MOLN's latest filing, from -$13121.8 in the prior quarter.
- Over the last five years, Enterprise Value for MOLN reached as high as -$13121.8 in Q4 2025 and fell as low as -$153.8 billion in Q1 2022.
- A 5-year average of -$37.0 billion and a median of -$258.6 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 113.25% — and 2026, when it soared 100.0%.
- Year by year, Enterprise Value stood at -$258.6 million in 2022, then grew by 18.53% to -$210.7 million in 2023, then climbed by 19.03% to -$170.6 million in 2024, then surged by 99.99% to -$13121.8 in 2025, then sank by 666.56% to -$100587.1 in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$100587.1, -$13121.8, and -$130662.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -100,587.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100,587.10 |
| Dec 31, 2025 | -13,121.83 |
| Sep 30, 2025 | -130,662.70 |
| Jun 30, 2025 | -39,368.74 |
| Mar 31, 2025 | -90.50 Bn |
| Dec 31, 2024 | -170.59 Mn |
| Sep 30, 2024 | -75.89 Bn |
| Jun 30, 2024 | -174.17 Mn |
| Mar 31, 2024 | -78.30 Bn |
| Dec 31, 2023 | -210.69 Mn |
| Sep 30, 2023 | -77.44 Bn |
| Jun 30, 2023 | -242.67 Mn |
| Mar 31, 2023 | -79.93 Bn |
| Dec 31, 2022 | -258.62 Mn |
| Sep 30, 2022 | -72.17 Bn |
| Jun 30, 2022 | -295.98 Mn |
| Mar 31, 2022 | -153.78 Bn |
| Dec 31, 2021 | -144.04 Mn |
| Sep 30, 2021 | -90.29 Bn |
| Jun 30, 2021 | -138.80 Mn |